Literature DB >> 9423664

Carcinoid metastases to the liver: role of triple-phase helical CT.

E K Paulson1, V G McDermott, M T Keogan, D M DeLong, M G Frederick, R C Nelson.   

Abstract

PURPOSE: To evaluate triple-phase helical computed tomography (CT) of carcinoid liver metastases.
MATERIALS AND METHODS: Triple-phase helical CT was performed in 31 patients with proved carcinoid liver metastases. Hepatic arterial-dominant phase (HAP) and portal venous-dominant phase (PVP) images were obtained 20 and 70 seconds after intravenous iopamidol injection. Four independent readers reviewed each phase for lesion number, conspicuity, and attenuation relative to liver. Three readers reviewed each phase to determine which phase best showed the lesions.
RESULTS: The lesions detected by readers 1-4 were as follows: noncontrast phase, 164, 177, 204, and 229 lesions; HAP, 178, 177, 214, and 238 lesions; and PVP, 180, 189, 215, and 250 lesions (P > .05). On HAP images, readers found that 80, 73, 96, and 102 lesions were hyperattenuating. Consensus indicated there were 206 focal lesions. Of these 206 lesions, 72, 72, and 62 lesions were best seen on the noncontrast phase, HAP, and PVP images, respectively. Six, 28, and six lesions were seen only on the noncontrast phase, HAP, and PVP images, respectively. Two patients had lesions seen only on the HAP images.
CONCLUSION: The HAP and, to a lesser extent, the noncontrast phase provide added value in evaluating carcinoid liver metastasis.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9423664     DOI: 10.1148/radiology.206.1.9423664

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  30 in total

Review 1.  MDCT of benign liver tumors and metastases.

Authors:  Pierre-Jean Valette; Frank Pilleul; Arielle Crombé-Ternamian
Journal:  Eur Radiol       Date:  2003-12       Impact factor: 5.315

2.  Standardisation of liver MDCT by tracking liver parenchyma enhancement to trigger imaging.

Authors:  H Brodoefel; A Tognolini; G A Zamboni; S Gourtsoyianni; C D Claussen; V Raptopoulos
Journal:  Eur Radiol       Date:  2011-11-05       Impact factor: 5.315

3.  Assessment of Added Value of Noncontrast to Contrast-Enhanced Abdominal Computed Tomography Scan for Characterization of Hypervascular Liver Metastases.

Authors:  Gelareh Sadigh; Sadhna B Nandwana; Courtney Moreno; Kelly L Cox; Deborah A Baumgarten; Jeffrey Switchenko; Tiffany Easter; Kimberly E Applegate
Journal:  Curr Probl Diagn Radiol       Date:  2016-05-25

4.  Detection of hypervascular hepatocellular carcinoma: Comparison of multi-detector CT with digital subtraction angiography and Lipiodol CT.

Authors:  Xiao-Hua Zheng; Yong-Song Guan; Xiang-Ping Zhou; Juan Huang; Long Sun; Xiao Li; Yuan Liu
Journal:  World J Gastroenterol       Date:  2005-01-14       Impact factor: 5.742

Review 5.  Medullary thyroid cancer: monitoring and therapy.

Authors:  Douglas W Ball
Journal:  Endocrinol Metab Clin North Am       Date:  2007-09       Impact factor: 4.741

6.  Re-evaluation of detectability of liver metastases by contrast-enhanced CT: added value of hepatic arterial phase imaging.

Authors:  Yukiko Honda; Toru Higaki; Haruka Higashihori; Yoshio Monzen; Fuminari Tatsugami; Shuji Date; Kazuo Awai
Journal:  Jpn J Radiol       Date:  2014-05-23       Impact factor: 2.374

7.  Imaging of gastroenteropancreatic neuroendocrine tumors.

Authors:  Eik Hock Tan; Cher Heng Tan
Journal:  World J Clin Oncol       Date:  2011-01-10

Review 8.  Calcified liver metastases from a non-functioning pancreatic neuroendocrine tumor.

Authors:  Terufumi Kawamoto; Tsunekazu Hishima; Kiminori Kimura
Journal:  Clin J Gastroenterol       Date:  2014-08-29

Review 9.  Imaging of liver cancer.

Authors:  Ben Ariff; Claire R Lloyd; Sameer Khan; Mohamed Shariff; Andrew V Thillainayagam; Devinder S Bansi; Shahid A Khan; Simon D Taylor-Robinson; Adrian K P Lim
Journal:  World J Gastroenterol       Date:  2009-03-21       Impact factor: 5.742

10.  [Oncologic imaging: indications for and limitations of modern cross-sectional imaging techniques].

Authors:  M E Mayerhoefer; A Ba-Ssalamah; H Prosch
Journal:  Radiologe       Date:  2013-04       Impact factor: 0.635

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.